TROP-2 expression in triple-negative and human epidermal growth factor receptor 2 enriched breast cancers and its relationship with clinicopathologic parameters
Polish Journal of Pathology · 28.11.2025 · 76 (3) · 248-256
DOI: 10.5114/pjp.2025.156555 ↗Kurz gefasst
Fachartikel in der Zeitschrift Polish Journal of Pathology, online erschienen am 28.11.2025. Verfasst von Hale Kivrak und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, Gülhane Research and Training Hospital, University of Health Sciences, Ankara, Turkey. karadag.hale@gmail.com. Hauptthemen laut MEDLINE: Antigens, Neoplasm, Triple Negative Breast Neoplasms, Erb-b2 Receptor Tyrosine Kinases, Biomarkers, Tumor. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 20 Literaturangaben.
Abstract (Originalsprache)
TROP-2 is a transmembrane calcium signaling molecule that is detected at a high rate (63%) in breast cancers. There are conflicting data on its relationship with subtypes, clinical, and pathological data in breast cancer.
TROP-2 expression levels were evaluated by immunohistochemistry, and the H-score method was used to analyze the data. This evaluation was conducted on a total of 79 patients diagnosed with triple-negative breast cancer (TNBC) and human epidermal growth factor receptor 2 (HER2) positive (HER2-E) breast cancer. The study also investigated the relationship between TROP-2 expression levels and the clinical-pathological features observed in patients diagnosed with TNBC and HER2-E. A total of 62 TNBC (78.5%) and 17 HER2-E (21.5%) cases were analyzed in the study.
The presence of high TROP-2 (H-score > 100) was detected in 87% of the TNBC group and 94% of the HER2-E group.
Among the pathological parameters, only low H-score values were found to have a statistically significant correlation with mucinous morphology; however, no significant correlation was found with other pathological parameters, including CerbB2 expression status. No significant relationship was found between H-score and clinical parameters. Furthermore, TROP-2 expression in HER2-E cancers is notably elevated. Further studies with larger series are required to clarify expression rates in mucinous tumors.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pathology, Gülhane Research and Training Hospital, University of Health Sciences, Ankara, Turkey. karadag.hale@gmail.com.
- Department of Pathology, Gülhane Research and Training Hospital, University of Health Sciences, Ankara, Turkey.
- Department of Pathology, Silifke State Hospital, Silifke/Mersin, Turkey.
- Department of Medical Oncology, Gülhane Research and Training Hospital, University of Health Sciences, Ankara, Turkey.
Zitieren
APA
Kivrak, H., Simsek, D., Akincioglu, E., Seçinti, I., Keskin, G., Erturk, I., & Demiriz, M. (2025). TROP-2 expression in triple-negative and human epidermal growth factor receptor 2 enriched breast cancers and its relationship with clinicopathologic parameters. Polish Journal of Pathology, 76(3), 248-256. https://doi.org/10.5114/pjp.2025.156555
Vancouver
Kivrak H, Simsek D, Akincioglu E, Seçinti I, Keskin G, Erturk I, et al. TROP-2 expression in triple-negative and human epidermal growth factor receptor 2 enriched breast cancers and its relationship with clinicopathologic parameters. Polish Journal of Pathology. 2025;76(3):248-256. doi:10.5114/pjp.2025.156555
BibTeX
@article{Kivrak2025,
author = {Kivrak, Hale and Simsek, Duygu and Akincioglu, Egemen and Seçinti, Ilke and Keskin, Gül and Erturk, Ismail and Demiriz, Murat},
title = {TROP-2 expression in triple-negative and human epidermal growth factor receptor 2 enriched breast cancers and its relationship with clinicopathologic parameters},
journal = {Polish Journal of Pathology},
year = {2025},
volume = {76},
number = {3},
pages = {248--256},
doi = {10.5114/pjp.2025.156555}
}
EUVIMED